diazepam has been researched along with rabeprazole in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chiba, K; Hayashi, M; Horai, Y; Ishizaki, T; Koyama, E; Manabe, K; Tomono, Y; Toyoki, T; Yamato, C; Yasuda, S | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
1 review(s) available for diazepam and rabeprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for diazepam and rabeprazole
| Article | Year |
|---|---|
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Diazepam; Drug Interactions; Half-Life; Humans; Hydroxylation; Male; Mephenytoin; Mixed Function Oxygenases; Nordazepam; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Reference Values; Single-Blind Method | 1995 |
5 other study(ies) available for diazepam and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |